Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 5/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 8/20 | 0.48 |
| ▸ | MIF | P14174 | 4/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | BACH1 | O14867 | 1/20 | 0.42 |
| ▸ | MAFK | O60675 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1607282 | 1.00 | NAAA (0.54) | NAAATRPA1MIFGSK3BKEAP1 | |
| SCHEMBL5070755 | 1.00 | NAAA (0.54) | NAAATRPA1MIFGSK3BKEAP1 | |
| SCHEMBL1607124 | 1.00 | NAAA (0.54) | NAAATRPA1MIFGSK3BKEAP1 | |
| SCHEMBL1607149 | 1.00 | NAAA (0.54) | NAAATRPA1MIFGSK3BKEAP1 | |
| SCHEMBL14933784 | 1.00 | NAAA (0.54) | NAAATRPA1MIFGSK3BKEAP1 | |
| SCHEMBL14933787 | 1.00 | NAAA (0.54) | NAAATRPA1MIFGSK3BKEAP1 | |
| SCHEMBL25332541 | 1.00 | NAAA (0.54) | NAAATRPA1MIFGSK3BKEAP1 | |
| SCHEMBL106183 | 1.00 | NAAA (0.54) | NAAATRPA1MIFGSK3BKEAP1 | |
| SCHEMBL2485837 | 1.00 | NAAA (0.54) | NAAATRPA1MIFGSK3BKEAP1 | |
| Sulforaphane SCHEMBL20855320 | 0.98 | NAAA (0.50) | NAAATRPA1MIFGSK3BKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3820290-B1 | FUNGICIDES TO PREVENT AND CONTROL FUNGAL PATHOGENS | UNIV LAUSANNE (CH) | 2025-07-02 | — | — | EP | claimed |
| US-12167731-B2 | Fungicides to prevent and control fungal pathogens | UNIVERSITE DE LAUSANNE (CH) | 2024-12-17 | — | — | US | claimed |
| CN-112469279-B | Fungicides for the prevention and control of fungal pathogens | 洛桑大学 | 2022-05-31 | — | — | CN | claimed |
| EP-1313377-B1 | TREATMENT OF HELICOBACTER WITH ISOTHIOCYANATES | FAHEY JED W (US) | 2015-01-21 | — | — | EP | claimed |
| US-20090326056-A1 | NOVEL ACTIVES AGAINST PROSTATE CARCINOMA | DSM IP ASSETS B.V. (NL) | 2009-12-31 | — | — | US | claimed |
| EP-1569628-B1 | NOVEL USE OF LYCOPENE FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ANDROGEN SIGNALLING | DSM IP ASSETS BV (NL) | 2009-07-22 | — | — | EP | claimed |
| US-20060258599-A1 | Methods and composition for the treatment of cystic fibrosis and related illnesses | CHILDERS MELANIE | 2006-11-16 | — | — | US | claimed |
| WO-2006065736-A2 | METHOD OF EXTRACTION OF ISOTHIOCYANATES INTO OIL FROM GLUCOSINOLSATE-CONTAINING PLANTS | JOHNS HOPKINS UNIVERSITY (US) | 2006-06-22 | — | — | WO | claimed |
| US-20060127996-A1 | Method of extraction of isothiocyanates into oil from glucosinolate-containing plants and method of producing products with oil containing isothiocyanates extracted from glucosinolate-containing plants | JOHNS HOPKINS UNIVERSITY | 2006-06-15 | — | — | US | claimed |
| US-20060069151-A1 | Novel use of lycopene | DSM IP ASSETS B.V. (NL) | 2006-03-30 | — | — | US | claimed |
| CN-1720030-A | The new purposes of lycopene | DSM IP ASSETS BV (NL) | 2006-01-11 | — | — | CN | claimed |
| EP-1569628-A1 | NOVEL USE OF LYCOPENE | DSM IP Assets B.V. (NL) | 2005-09-07 | — | — | EP | claimed |
| EP-1476143-A1 | COMPOSITIONS COMPRISING LYCOPENE FOR THE TREATMENT AND PREVENTION OF ANGIOGENESIS ASSOCIATED PATHOLOGIES | DSM IP Assets B.V. (NL) | 2004-11-17 | — | — | EP | claimed |
| US-20040180843-A1 | Treatment of helicobacter with isothocyanates | BRASSICA FOUNDATION FOR CHEMOPROTECTION RESEARCH, INC. | 2004-09-16 | — | — | US | claimed |
| WO-2004052351-A1 | NOVEL USE OF LYCOPENE | DSM IP ASSETS B.V. (CH) | 2004-06-24 | — | — | WO | claimed |
| US-6737441-B2 | PREVENTING OR TREATING PERSISTENT CHRONIC GASTRITIS, ULCERS AND/OR STOMACH CANCER | Fahey, Jed W. | 2004-05-18 | — | — | US | claimed |
| WO-2003068202-A1 | COMPOSITIONS COMPRISING LYCOPENE FOR THE TREATMENT AND PREVENTION OF ANGIOGENESIS ASSOCIATED PATHOLOGIES | DSM IP ASSETS B.V. (NL) | 2003-08-21 | — | — | WO | claimed |
| EP-1313377-A2 | TREATMENT OF HELICOBACTER WITH ISOTHIOCYANATES | Fahey, Jed W. (US) | 2003-05-28 | — | — | EP | claimed |
| US-20020151505-A1 | Treatment of helicobacter with isothiocyanates | FAHEY, JED W. | 2002-10-17 | — | — | US | claimed |
| WO-2002015722-A2 | TREATMENT OF HELICOBACTER WITH ISOTHIOCYANATES | FAHEY JED W (US) | 2002-02-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12167731-B2 | Fungicides to prevent and control fungal pathogens | ERG28, STS, GBA3 | NAAA 217/4885TRPA1 1853/4885MIF 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.